New Drug Reducing Progression of Primary Progressive MS
In this video from the Vall d’Hebron Barcelona Hospital Campus, Dr. Xavier Montalbán talks about the Phase 3 international study of a new drug developed by Roche called ocrelizumab. The clinical trials have shown that patients with primary progressive multiple sclerosis (PPMS) see a reduction of clinical progression in at least 12 weeks.
The new drug gives much hope for those who live with this relatively rare form of multiple sclerosis.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.